Data sharing is going on with WHO to give recognition to Bharat Biotech's Covaxin, the government said, noting that it wants to achieve this "milestone" as soon as possible.
Responding to a question on recognition of Covaxin by the WHO, NITI Aayog Member (Health) V K Paul said the government is pursuing it.
"We have been working with both Bharat Biotech and the WHO to make it happen. There is data sharing going on and we are very keen that this milestone is achieved as soon as possible. We are pursuing it," he said.
On May 24, Hyderabad-based Bharat Biotech International Limited (BBIL) conveyed to the government that it has already submitted 90 per cent of the documents to the WHO for obtaining emergency use listing (EUL) for the Covaxin vaccine.
The latest 'Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process' guidance document dated May 18 on the WHO website said Bharat Biotech submitted EOI (Expression of Interest) on April 19 and that "more information (is) required".
A pre-submission meeting is expected "to be planned May-June 2021", the guidance document said.
According to the WHO, submissions to it for prequalification or listing under the emergency use procedure are confidential.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU